Sensei Biotherapeutics (NASDAQ:SNSE) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors. The bad news for Sensei Biotherapeutics comes from its results in this trial. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn’t seem to be sittin ...